T0	Participants 51 79	transurethral prostatectomy.
T1	Participants 92 171	599 evaluable patients with benign prostatic hypertrophy at 7 urological units.
T2	Participants 179 206	transurethral prostatectomy
T3	Participants 251 351	group 1--197 patients given single-dose ceftriaxone (2 gm.), group 2--203 patients given 160/800 mg.
T4	Participants 352 442	trimethoprimsulfamethoxazole and group 3--199 controls given no antimicrobial prophylaxis.
T5	Participants 443 594	Patients with a preoperative indwelling catheter, positive urine culture, signs of active infection or preoperative antibiotic treatment were excluded.
T6	Participants 1044 1072	transurethral prostatectomy.